Literature DB >> 8405513

Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol.

R Wenzl1, H C Bennink, A van Beek, J Spona, J Huber.   

Abstract

OBJECTIVE: To evaluate ovarian function by ultrasonography and endocrine measurements.
DESIGN: Prospective, open study.
SETTING: Outpatient clinic of the First Department of Gynaecology and Obstetrics, University of Vienna, Austria. PARTICIPANTS: Twenty healthy women with regular cycles and established ovulation by ultrasonography. INTERVENTION: Treatment with a combination of 1 mg micronized E2 with 150 micrograms desogestrel daily for 21 days, followed by 7 pill-free days. MAIN OUTCOME MEASURES: Transvaginal ultrasonography and estimation of E2 and P at least twice a week for two consecutive cycles, followed by one after treatment cycle.
RESULTS: Ovulation inhibition was apparent in all cases and no functional ovarian cysts were observed during treatment. On a few occasions a persistent follicle was noted, but in the majority of cases there was total absence of follicular activity. The bleeding pattern showed a tendency toward prolonged and more heavy bleeding when compared with the before treatment situation. Return of ovulation was prompt in all women but one.
CONCLUSIONS: Ultrasonographic observations, accompanied by P and E2 measurements, allow us to conclude that the combination of 1 mg E2 with 150 micrograms desogestrel provides complete ovulation inhibition. However, the bleeding pattern does not show an acceptable profile.

Entities:  

Keywords:  Austria; Biology; Bleeding; Clinical Research; Contraception; Contraceptive Agents, Female--pharmacodynamics; Contraceptive Agents, Progestin--pharmacodynamics; Contraceptive Agents--pharmacodynamics; Contraceptive Methods; Contraceptive Mode Of Action; Desogestrel--pharmacodynamics; Developed Countries; Diseases; Endocrine System; Estradiol--pharmacodynamics; Estrogens; Europe; Family Planning; Genitalia; Genitalia, Female; Hormones; Oral Contraceptives; Oral Contraceptives, Combined; Ovarian Effects; Ovary; Ovulation Suppression; Physiology; Research Methodology; Research Report; Signs And Symptoms; Urogenital System; Western Europe

Mesh:

Substances:

Year:  1993        PMID: 8405513     DOI: 10.1016/s0015-0282(16)56210-4

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  8 in total

1.  Metabolic and haemostatic effects of estradiol valerate/dienogest, a novel oral contraceptive: a randomized, open-label, single-centre study.

Authors:  Wolfgang Junge; Uwe Mellinger; Susanne Parke; Marco Serrani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

2.  Hemostatic effects of a novel estradiol-based oral contraceptive: an open-label, randomized, crossover study of estradiol valerate/dienogest versus ethinylestradiol/levonorgestrel.

Authors:  Christine Klipping; Ingrid Duijkers; Susanne Parke; Uwe Mellinger; Marco Serrani; Wolfgang Junge
Journal:  Drugs R D       Date:  2011

3.  Endometrial safety of an oral contraceptive containing estradiol valerate and dienogest.

Authors:  Johannes Bitzer; Susanne Parke; Thomas Roemer; Marco Serrani
Journal:  Int J Womens Health       Date:  2011-04-18

4.  Efficacy and tolerability of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in a 24/4 regimen, in comparison to an oral contraceptive containing ethinylestradiol and drospirenone in a 21/7 regimen.

Authors:  Diana Mansour; Carole Verhoeven; Werner Sommer; Edith Weisberg; Surasak Taneepanichskul; Gian Benedetto Melis; Inger Sundström-Poromaa; Tjeerd Korver
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-10-13       Impact factor: 1.848

5.  Effects of a monophasic combined oral contraceptive containing nomegestrol acetate and 17β-oestradiol in comparison to one containing levonorgestrel and ethinylestradiol on markers of endocrine function.

Authors:  Ulla M Ågren; Marjatta Anttila; Kristiina Mäenpää-Liukko; Maija-Liisa Rantala; Hilkka Rautiainen; Werner F Sommer; Ellen Mommers
Journal:  Eur J Contracept Reprod Health Care       Date:  2011-09-26       Impact factor: 1.848

Review 6.  An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate/dienogest.

Authors:  Franca Fruzzetti; Florence Trémollieres; Johannes Bitzer
Journal:  Gynecol Endocrinol       Date:  2012-04-02       Impact factor: 2.260

7.  Nomegestrol acetate-17b-estradiol for oral contraception.

Authors:  Anne Burke
Journal:  Patient Prefer Adherence       Date:  2013-06-27       Impact factor: 2.711

8.  Contraceptive efficacy and safety of estradiol valerate/dienogest in a healthy female population: a multicenter, open-label, uncontrolled Phase III study.

Authors:  Qi Yu; Zirong Huang; Mulan Ren; Qing Chang; Zhongqi Zhang; Susanne Parke
Journal:  Int J Womens Health       Date:  2018-06-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.